Analysis of Long-term (Investment) Activity Ratios
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Illumina Inc., long-term (investment) activity ratios
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Illumina Inc. net fixed asset turnover ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Illumina Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2018 to 2019 and from 2019 to 2020. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Illumina Inc. total asset turnover ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Illumina Inc. equity turnover ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Net Fixed Asset Turnover
Illumina Inc., net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239 | 3,543 | 3,333 | 2,752 | 2,398 | |
| Property and equipment, net | 922 | 889 | 1,075 | 931 | 713 | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 3.51 | 3.99 | 3.10 | 2.96 | 3.36 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 8.73 | 11.23 | 11.36 | 10.07 | 9.85 | |
| Amgen Inc. | 4.96 | 4.51 | 4.54 | 4.37 | 4.41 | |
| Eli Lilly & Co. | 2.83 | 2.83 | 2.75 | 2.59 | 2.57 | |
| Gilead Sciences Inc. | 4.90 | 4.91 | 5.41 | 7.79 | 10.45 | |
| Johnson & Johnson | 4.40 | 4.65 | 4.79 | 4.50 | 4.52 | |
| Merck & Co. Inc. | 2.67 | 3.11 | 3.18 | 3.23 | 3.31 | |
| Moderna Inc. | 0.67 | 0.00 | 0.00 | — | — | |
| Pfizer Inc. | 3.01 | 3.71 | 4.01 | 3.79 | 3.97 | |
| Regeneron Pharmaceuticals Inc. | 2.64 | 2.72 | 2.61 | 2.49 | 2.33 | |
| Thermo Fisher Scientific Inc. | 5.45 | 5.38 | 5.85 | 5.17 | 7.09 | |
| Zoetis Inc. | 3.03 | 3.23 | 3.51 | 3.70 | 3.54 | |
| Net Fixed Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 3.94 | 4.17 | 4.32 | 4.22 | 4.41 | |
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | 7.14 | 7.21 | 7.01 | 6.96 | 7.16 | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Net fixed asset turnover = Revenue ÷ Property and equipment, net
= 3,239 ÷ 922 = 3.51
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Illumina Inc. net fixed asset turnover ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Illumina Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239 | 3,543 | 3,333 | 2,752 | 2,398 | |
| Property and equipment, net | 922 | 889 | 1,075 | 931 | 713 | |
| Operating lease right-of-use assets | 532 | 555 | — | — | — | |
| Property and equipment, net (including operating lease, right-of-use asset) | 1,454 | 1,444 | 1,075 | 931 | 713 | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 2.23 | 2.45 | 3.10 | 2.96 | 3.36 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
| AbbVie Inc. | 7.46 | 10.06 | 11.36 | 10.07 | 9.85 | |
| Amgen Inc. | 4.58 | 4.11 | 4.54 | 4.37 | 4.41 | |
| Eli Lilly & Co. | 2.63 | 2.66 | 2.75 | 2.59 | 2.57 | |
| Gilead Sciences Inc. | 4.34 | 4.28 | 5.41 | 7.79 | 10.45 | |
| Johnson & Johnson | 4.18 | 4.41 | 4.79 | 4.50 | 4.52 | |
| Merck & Co. Inc. | 2.43 | 2.90 | 3.18 | 3.23 | 3.31 | |
| Moderna Inc. | 0.52 | 0.00 | 0.00 | — | — | |
| Pfizer Inc. | 2.74 | 3.39 | 4.01 | 3.79 | 3.97 | |
| Regeneron Pharmaceuticals Inc. | 2.62 | 2.70 | 2.61 | 2.49 | 2.33 | |
| Thermo Fisher Scientific Inc. | 4.82 | 4.69 | 5.85 | 5.17 | 7.09 | |
| Zoetis Inc. | 2.79 | 2.94 | 3.51 | 3.70 | 3.54 | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 3.61 | 3.85 | 4.32 | 4.22 | 4.41 | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry | ||||||
| Health Care | 5.75 | 5.83 | 7.01 | 6.96 | 7.16 | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property and equipment, net (including operating lease, right-of-use asset)
= 3,239 ÷ 1,454 = 2.23
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Illumina Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2018 to 2019 and from 2019 to 2020. |
Total Asset Turnover
Illumina Inc., total asset turnover calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239 | 3,543 | 3,333 | 2,752 | 2,398 | |
| Total assets | 7,585 | 7,316 | 6,959 | 5,257 | 4,281 | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.43 | 0.48 | 0.48 | 0.52 | 0.56 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 0.30 | 0.37 | 0.55 | 0.40 | 0.39 | |
| Amgen Inc. | 0.39 | 0.37 | 0.34 | 0.27 | 0.28 | |
| Eli Lilly & Co. | 0.53 | 0.57 | 0.56 | 0.51 | 0.55 | |
| Gilead Sciences Inc. | 0.36 | 0.36 | 0.34 | 0.37 | 0.53 | |
| Johnson & Johnson | 0.47 | 0.52 | 0.53 | 0.49 | 0.51 | |
| Merck & Co. Inc. | 0.52 | 0.55 | 0.51 | 0.46 | 0.42 | |
| Moderna Inc. | 0.03 | 0.00 | 0.00 | — | — | |
| Pfizer Inc. | 0.27 | 0.31 | 0.34 | 0.31 | 0.31 | |
| Regeneron Pharmaceuticals Inc. | 0.50 | 0.53 | 0.57 | 0.67 | 0.70 | |
| Thermo Fisher Scientific Inc. | 0.47 | 0.44 | 0.43 | 0.37 | 0.40 | |
| Zoetis Inc. | 0.49 | 0.54 | 0.54 | 0.62 | 0.64 | |
| Total Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.40 | 0.43 | 0.45 | 0.40 | 0.41 | |
| Total Asset Turnover, Industry | ||||||
| Health Care | 0.64 | 0.65 | 0.67 | 0.66 | 0.68 | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Total asset turnover = Revenue ÷ Total assets
= 3,239 ÷ 7,585 = 0.43
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Illumina Inc. total asset turnover ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
Equity Turnover
Illumina Inc., equity turnover calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239 | 3,543 | 3,333 | 2,752 | 2,398 | |
| Total Illumina stockholders’ equity | 4,694 | 4,613 | 3,758 | 2,749 | 2,197 | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | 0.69 | 0.77 | 0.89 | 1.00 | 1.09 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| AbbVie Inc. | 3.50 | — | — | 5.54 | 5.53 | |
| Amgen Inc. | 2.58 | 2.30 | 1.80 | 0.86 | 0.73 | |
| Eli Lilly & Co. | 4.35 | 8.56 | 2.50 | 1.97 | 1.52 | |
| Gilead Sciences Inc. | 1.34 | 0.98 | 1.01 | 1.26 | 1.59 | |
| Johnson & Johnson | 1.31 | 1.38 | 1.37 | 1.27 | 1.02 | |
| Merck & Co. Inc. | 1.90 | 1.81 | 1.58 | 1.17 | 0.99 | |
| Moderna Inc. | 0.08 | 0.00 | 0.00 | — | — | |
| Pfizer Inc. | 0.66 | 0.82 | 0.85 | 0.74 | 0.89 | |
| Regeneron Pharmaceuticals Inc. | 0.77 | 0.71 | 0.77 | 0.96 | 1.09 | |
| Thermo Fisher Scientific Inc. | 0.93 | 0.86 | 0.88 | 0.82 | 0.85 | |
| Zoetis Inc. | 1.77 | 2.31 | 2.67 | 3.00 | 3.29 | |
| Equity Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 1.36 | 1.46 | 1.40 | 1.15 | 1.10 | |
| Equity Turnover, Industry | ||||||
| Health Care | 1.91 | 1.93 | 1.93 | 1.83 | 1.81 | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Equity turnover = Revenue ÷ Total Illumina stockholders’ equity
= 3,239 ÷ 4,694 = 0.69
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Illumina Inc. equity turnover ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |